CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM099884
035-os BibID:(cikkazonosító)1037 (scopus)85122862338 (wos)000754896600001
Első szerző:Kiss Mariann (vegyész)
Cím:2-Acetamido-2-deoxy-d-glucono-1,5-lactone Sulfonylhydrazones: Synthesis and Evaluation as Inhibitors of Human OGA and HexB Enzymes / Mariann Kiss, István Timári, Teréz Barna, Zuzana Mészáros, Kristýna Slámová, Pavla Bojarová, Vladimír Křen, Joseph M. Hayes, László Somsák
Dátum:2022
ISSN:1661-6596 1422-0067
Megjegyzések:Inhibition of the human O-linked ?-N-acetylglucosaminidase (hOGA, GH84) enzyme is pharmacologically relevant in several diseases such as neurodegenerative and cardiovascular disorders, type 2 diabetes, and cancer. Human lysosomal hexosaminidases (hHexA and hHexB, GH20) are mechanistically related enzymes; therefore, selective inhibition of these enzymes is crucial in terms of potential applications. In order to extend the structure?activity relationships of OGA inhibitors, a series of 2-acetamido-2-deoxy-D-glucono-1,5-lactone sulfonylhydrazones was prepared from D-glucosamine. The synthetic sequence involved condensation of N-acetyl-3,4,6-tri-O-acetylD-glucosamine with arenesulfonylhydrazines, followed by MnO2 oxidation to the corresponding glucono-1,5-lactone sulfonylhydrazones. Removal of the O-acetyl protecting groups by NH3/MeOH furnished the test compounds. Evaluation of these compounds by enzyme kinetic methods against hOGA and hHexB revealed potent nanomolar competitive inhibition of both enzymes, with no significant selectivity towards either. The most efficient inhibitor of hOGA was 2-acetamido-2-deoxyD-glucono-1,5-lactone 1-naphthalenesulfonylhydrazone (5f, Ki = 27 nM). This compound had a Ki of 6.8 nM towards hHexB. To assess the binding mode of these inhibitors to hOGA, computational studies (Prime protein?ligand refinement and QM/MM optimizations) were performed, which suggested the binding preference of the glucono-1,5-lactone sulfonylhydrazones in an s-cis conformation for all test compounds.
Tárgyszavak:Természettudományok Kémiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
hOGA
hHexB
inhibitor
glyconolactone sulfonylhydrazone
Prime refinement
QM/MM optimization
Megjelenés:International Journal of Molecular Sciences. - 23 : 3 (2022), p. 1-18. --
További szerzők:Timári István (1989-) (vegyész) Barna Teréz (1963-) (vegyész) Mészáros, Zuzana Slámová, Kristýna Bojarová, Pavla Křen, Vladimír Hayes, Joseph M. Somsák László (1954-) (vegyész)
Pályázati támogatás:K109450
OTKA
FK-125067
OTKA
PD 135034
OTKA
GINOP-2.3.2-15-2016-00008
GINOP
GINOP-2.3.3-15-2016-00004
GINOP
ÚNKP-21-5-DE-471
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM096569
035-os BibID:(cikkazonosító)113649 (WoS)000695696100030 (Scopus)85109505021
Első szerző:Kiss Mariann (vegyész)
Cím:Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives / Mariann Kiss, Erna Szabó, Boglárka Bocska, Luu Thanh Sinh, Conceicao Piedade Fernandes, István Timári, Joseph M. Hayes, László Somsák, Teréz Barna
Dátum:2021
ISSN:0223-5234
Megjegyzések:O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked beta-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single beta-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively. The perturbed homeostasis of O-GlcNAc cycling results in several pathological conditions. Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease. A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-D-glucono-1,5-lactone (thio)semicarbazones, have been identified. Eight inhibitors were designed and synthesized in five steps starting from d-glucosamine and with 15-55% overall yields. A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph. Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability. From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with K-i-s in the range of similar to 30-250 nM and moderate selectivity with respect to lysosomal beta-hexosaminidases. In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-D-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (K-i = 36 nM). The protocol employed has applications in future structure based inhibitor design targeting OGA. (C) 2021 The Authors. Published by Elsevier Masson SAS.
Tárgyszavak:Természettudományok Kémiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
hOGA
Expression
Inhibitor
Glyconolactone semicarbazone
QM/MM-PBSA
Halogen
HalogenHydrogen bond donor
Megjelenés:European Journal of Medicinal Chemistry. - 223 (2021), p. 1-14. -
További szerzők:Szabó Erna (1990-) (Biológus) Bocska Boglárka Sinh, Luu Thanh Fernandes, Conceicao Piedade Timári István (1989-) (vegyész) Hayes, Joseph M. Somsák László (1954-) (vegyész) Barna Teréz (1963-) (vegyész)
Pályázati támogatás:K 109450
OTKA
NKFIH FK125067
Egyéb
NKFIH PD 135034
Egyéb
GINOP-2.3.2-15-2016-00008
GINOP
GINOP-2.3.3-15-2016-00004
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1